跳转至内容
Merck
CN
  • A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Leukemia (2014-10-07)
L Zhou, Y Zhang, S Chen, M Kmieciak, Y Leng, H Lin, K A Rizzo, C I Dumur, A Ferreira-Gonzalez, Y Dai, S Grant
摘要

AZD1775 targets the cell cycle checkpoint kinase Wee1 and potentiates genotoxic agent cytotoxicity through p53-dependent or -independent mechanisms. Here, we report that AZD1775 interacted synergistically with histone deacetylase inhibitors (HDACIs, for example, Vorinostat), which interrupt the DNA damage response, to kill p53-wild type (wt) or -deficient as well as FLT3-ITD leukemia cells in association with pronounced Wee1 inhibition and diminished cdc2/Cdk1 Y15 phosphorylation. Similarly, Wee1 shRNA knockdown significantly sensitized cells to HDACIs. Although AZD1775 induced Chk1 activation, reflected by markedly increased Chk1 S296/S317/S345 phosphorylation leading to inhibitory T14 phosphorylation of cdc2/Cdk1, these compensatory responses were sharply abrogated by HDACIs. This was accompanied by premature mitotic entry, multiple mitotic abnormalities and accumulation of early S-phase cells displaying increased newly replicated DNA, culminating in robust DNA damage and apoptosis. The regimen was active against patient-derived acute myelogenous leukemia (AML) cells harboring either wt or mutant p53 and various next-generation sequencing-defined mutations. Primitive CD34(+)/CD123(+)/CD38(-) populations enriched for leukemia-initiating progenitors, but not normal CD34(+) hematopoietic cells, were highly susceptible to this regimen. Finally, combining AZD1775 with Vorinostat in AML murine xenografts significantly reduced tumor burden and prolonged animal survival. A strategy combining Wee1 with HDACI inhibition warrants further investigation in AML with poor prognostic genetic aberrations.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙醇,Pure 200纯度, Molecular Biology
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
乙醇,Pure 190纯度, for molecular biology
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
酒精, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
无水乙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Sigma-Aldrich
酒精, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
酒精, standard for GC
Sigma-Aldrich
SAHA, ≥98% (HPLC)
Sigma-Aldrich
酒精, puriss. p.a., absolute, ≥99.8% (GC)
Supelco
Ethanol 溶液, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
酒精, tested according to Ph. Eur.
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
Sigma-Aldrich
次异羟肟酸, 95%
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
SBHA, A cell-permeable bishydroxamic acid histone deacetylase (HDAC) inhibitor with anti-tumor properties.
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
酒精, absolute, sales not in Germany, ≥99.8% (vol.)
Sigma-Aldrich
纯乙醇, 160 proof, Excise Tax-free, Permit for use required